为解决异基因造血干细胞移植（allo-HSCT）中急性移植物抗宿主病（aGVHD）这一威胁生命的并发症问题，研究人员开展了干细胞输注时间对 aGVHD 影响的研究。结果发现清晨输注可降低 aGVHD 发生率和严重程度，提高生存率。这为预防 aGVHD 提供了新策略。 异基因造血 ...

Dr. John Koreth from the Dana-Farber Cancer Institute highlighted the absence of approved first-line therapies for aGVHD and the significance of itolizumab’s efficacy in longer-term outcomes.

Despite the lack of improvement in early response rates, the company reported that itolizumab showed a favorable safety profile and did not increase the risk of infections or sepsis, which are common ...